TransCode Therapeutics, Inc. intends to file a request for a hearing before a Nasdaq Hearings Panel in response to a notice from Nasdaq stating that the company has not regained compliance with the Minimum Bid Price Rule and may be delisted from The Nasdaq Capital Market.